多发性骨髓瘤新型治疗方案的研究进展
千晨静， 洪梅， 夏凌辉 - 肿瘤防治研究, 2023 - zlfzyj.com
… by response to initial treatment and eventual resistance. Despite major advances in the
clinical treatment of multiple myeloma driven by the introduction of new drugs (eg, proteasome …
clinical treatment of multiple myeloma driven by the introduction of new drugs (eg, proteasome …
[PDF][PDF] 骨髓瘤骨病的研究进展
刘旭剑， 张匣， 张谦倩， 冯和林 - 肿瘤, 2020 - tumorsci.org
… Myeloma bone disease (MBD) is the most common complication of multiple myeloma (MM). …
the development of new drugs and the treatment of MBD and MM. This article reviews the …
the development of new drugs and the treatment of MBD and MM. This article reviews the …
组蛋白去乙酰化酶抑制剂对多发性骨髓瘤细胞的杀伤机制及临床应用现状
苑冬阳， 高欣， 杨融辉， 张萌， 廖爱军 - 中国肿瘤临床, 2018 - cjco.cn
… Abstract Multiple myeloma (MM) is a malignant plasmacytoma that remains incurable. Over
the … romidepsin for the treatment of refractory multiple myeloma [J]. Cancer, 2011, 117(2):336. …
the … romidepsin for the treatment of refractory multiple myeloma [J]. Cancer, 2011, 117(2):336. …
[PDF][PDF] 多发性骨髓瘤骨病中西医结合治疗研究进展
钱树树， 张弘， 代会博， 马邦云， 沙小草， 孙雪梅 - 中国中西医结合杂志, 2022 - cjim.cn
… 多发性骨髓瘤(multiple myeloma,MM)是 一种以骨髓中单克隆浆细胞恶性增殖为特征的浆细
胞… 性骨折等骨骼病变,即多发性骨髓瘤骨 病(multiple myeloma bone disease,MBD)[1]. 40%~50%…
胞… 性骨折等骨骼病变,即多发性骨髓瘤骨 病(multiple myeloma bone disease,MBD)[1]. 40%~50%…
树状大分子用于肿瘤诊疗原则的最新治疗应用
S Mignani, J Rodrigues, H Tomas, AM Caminade… - Science China …, 2018 - Springer
… dendrimers bearing different contrast agents and drugs, such as cytotoxic compounds in
the oncology domain. Dendrimers emerged as a new class of highly tunable hyperbranched …
the oncology domain. Dendrimers emerged as a new class of highly tunable hyperbranched …
[PDF][PDF] 唑来膦酸用于急性椎体骨折性疼痛的疗效观察
王静， 夏令杰， 陶熔， 马松鹤， 姜迎海 - 中国药房, 2015 - china-pharmacy.com
… of denosumab versus zoledronic Acid in the treatment of bone metastases in patients with
advanced cancer(excluding breast and prostate cancer)or multiple myeloma[J]. J Clin Oncol,…
advanced cancer(excluding breast and prostate cancer)or multiple myeloma[J]. J Clin Oncol,…
[HTML][HTML] 生物信息学和网络药理学分析槲皮素靶向BIRC5 抑制胶质母细胞瘤的增殖并影响预后
胡阳春， 陈宇， 舒磊， 夏志宇， 代兴亮 - Advances in Clinical Medicine, 2023 - hanspub.org
… the target BIRC5, thereby affecting the prognosis of glioblastoma patients, providing a
new idea for the treatment of glioma and the development of new chemotherapeutic drugs. …
new idea for the treatment of glioma and the development of new chemotherapeutic drugs. …
长链非编码RNA 在衰老过程中的分子标志及其对衰老相关疾病的显著影响
SAM Sherazi, A Abbasi, MU Abdullah Jamil… - 中国神经再生研究 …, 2023 - sjzsyj.com.cn
Aging is linked to the deterioration of many physical and cognitive abilities and is the leading
risk factor for Alzheimer’s disease. The growing aging population is a significant healthcare …
risk factor for Alzheimer’s disease. The growing aging population is a significant healthcare …
组蛋白去乙酰化酶抑制剂及其衍生的多靶点抑制剂在胃肠道肿瘤中的研究进展
李显， 丁杰， 夏宇， 岑祥莹， 吴明， 张林， 樊斐， 曾家兴… - 中国普通外科杂志, 2020 - zpwz.net
… by drug interaction may occur when drugs are used in combination. In order to avoid drug
… Histone deacetylase inhibitors in multiple myeloma:from bench to bedside.[J]. Int J Hematol, …
… Histone deacetylase inhibitors in multiple myeloma:from bench to bedside.[J]. Int J Hematol, …
[HTML][HTML] 免疫检查点TIGIT 在肺癌免疫治疗中的研究进展
吴洁琼， 任敦强， 毕焕焕， 易冰倩… - Chinese Journal of Lung …, 2022 - ncbi.nlm.nih.gov
T 细胞免疫球蛋白和免疫受体酪氨酸抑制基序结构域（ T cell immunoreceptor with immunoglobulin
and immunoreceptor tyrosine-based inhibition motif domain, TIGIT） 是近年新发现的免疫…
and immunoreceptor tyrosine-based inhibition motif domain, TIGIT） 是近年新发现的免疫…